These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 7196236)

  • 21. Modes and mechanisms of action of vasoactive drugs and especially of cyclandelate.
    Timmerman H
    Br J Clin Pract Suppl; 1984; 34():10-9. PubMed ID: 6430317
    [No Abstract]   [Full Text] [Related]  

  • 22. Cyclandelate in the treatment of cerebral arteriosclerosis.
    Hall P
    J Am Geriatr Soc; 1976 Jan; 24(1):41-5. PubMed ID: 811704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of cyclandelate on in vitro red blood cell deformability.
    Hall DW; van den Hoven WE
    Drugs; 1987; 33 Suppl 2():30-40. PubMed ID: 3622306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Investigation on spasmolytics. VIII. The metabolism of 3,5,5-trimethylcyclohexyl mandelate (Cyclandelate) (III).
    ERNSTING MJ; REKKER RF; TERSTEEGE HM; NAUTA WT
    Arzneimittelforschung; 1962 Jul; 12():691-4. PubMed ID: 13890672
    [No Abstract]   [Full Text] [Related]  

  • 25. The effect of cyclandelate in depressed and demented patients: a controlled study in psychogeriatric patients.
    Davies G; Hamilton S; Hendrickson E; Levy R; Post F
    Age Ageing; 1977 Aug; 6(3):156-62. PubMed ID: 331919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulatory effect of several cerebral circulatory drugs in man, with special reference to aminophylline, papaverine, cyclandelate, vincamine, prostaglandin E1 and isoxsuprine.
    Miyazaki M
    Jpn Circ J; 1978 Apr; 42(4):433-40. PubMed ID: 702768
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of cyclandelate on dementia.
    Westreich G; Alter M; Lundgren S
    Stroke; 1975; 6(5):535-8. PubMed ID: 1101457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Evidence of a pharmacokinetic-pharmacodynamic relationship between pharmaco-EEG in healthy subjects after administration of cyclandelate].
    Dimpfel W; Schober F; Wedekind W; Kleinbloesem C; Coors C
    Arzneimittelforschung; 1994 Sep; 44(9):999-1004. PubMed ID: 7986255
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized placebo-controlled double-blind cross-over study on antihypoxidotic effects of piracetam using psychophysiological measures in healthy volunteers.
    Schaffler K; Klausnitzer W
    Arzneimittelforschung; 1988 Feb; 38(2):288-91. PubMed ID: 3370078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclandelate versus flunarizine. A double-blind study in a selected group of patients with dementia.
    Albizzati MG; Bassi S; Calloni E; Sbacchi M; Piolti R; Frattola L
    Drugs; 1987; 33 Suppl 2():90-6. PubMed ID: 3304956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical efficacy and central mechanisms of cyclandelate in migraine: a double-blind placebo-controlled study.
    Siniatchkin M; Gerber WD; Vein A
    Funct Neurol; 1998; 13(1):47-56. PubMed ID: 9584874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The melting-point of cyclospasmol and the quantitative determination of small amounts of 3.5.5.-trimethylcyclohexyl phenylglyoxylate in same.
    REKKER RF; ERNSTING MJ; NAUTA WT
    Pharm Weekbl; 1956 Jan; 91(1):1-6. PubMed ID: 13310216
    [No Abstract]   [Full Text] [Related]  

  • 33. Effects of Cyclospasmol upon sensory parameters in patients recovering from cerebrovascular accidents.
    Sourander L; Blakemore CB
    Angiology; 1978 Feb; 29(2):133-8. PubMed ID: 347985
    [No Abstract]   [Full Text] [Related]  

  • 34. Cyclandelate in the treatment of senility: a controlled study.
    Capote B; Parikh N
    J Am Geriatr Soc; 1978 Aug; 26(8):360-2. PubMed ID: 353121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclandelate versus propranolol in the prophylaxis of migraine--a double-blind placebo-controlled study.
    Gerber WD; Schellenberg R; Thom M; Haufe C; Bölsche F; Wedekind W; Niederberger U; Soyka D
    Funct Neurol; 1995; 10(1):27-35. PubMed ID: 7649498
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of cyclospasmol on early diabetic retinopathy.
    Mota MC; Leite E; Ruas MA; Verjans HL; Blakemore CB; Cunha-Vaz JG
    Int Ophthalmol; 1987 Feb; 10(1):3-9. PubMed ID: 3549595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and tolerance of cyclandelate versus pizotifen in the prophylaxis of migraine.
    Mastrosimone F; Iaccarino C; de Caterina G
    J Med; 1992; 23(1):1-16. PubMed ID: 1573338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Vigilance behavior in interaction of the serotonin-selective antidepressant zimelidine and parenterally administered ethanol].
    Schaffler K; Arnold H; Hörmann E
    Arzneimittelforschung; 1982; 32(8):845-52. PubMed ID: 6215927
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determination of plasma concentrations of cyclandelate and mandelic acid in patients with generalized atherosclerotic vasculopathy treated with oral cyclandelate.
    Forconi S; Cappelli R; Guerrini M; Volpi L; Frigerio C; Di Perri T
    J Int Med Res; 1990; 18(4):266-72. PubMed ID: 2227073
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Efficacy of an etofylline-cyclandelate combination in age-dependent cerebrovascular insufficiency].
    Foltyn P; Lücker PW; Schnitker J
    Arzneimittelforschung; 1982; 32(10):1322-8. PubMed ID: 6891235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.